Recent events
Recent events tied to this brand in public sources.
Back to profile76 entries · Page 2 of 4
2021
Merck and Innervia agree to develop bioelectronic therapies
Merck and Innervia entered a collaboration to jointly develop next-generation graphene-based bioelectronic vagus nerve therapies targeting diseases in Merck's target therapy areas.
2021
Facebook and Merck announce a multi-year initiative
Facebook and Merck announced a multi-year initiative with other companies and organizations to research and promote how online platforms can address vaccine hesitancy. Each committed $20 million to the initiative.
2021
Merck KGaA exercises a third option in its collaboration with F-star
Ares Trading S.A., an affiliate of Merck KGaA, exercised its third option under the ongoing collaboration with F-star to license an additional preclinical program. Merck KGaA will take over future development and commercialization of the program.
2021
Merck completed acquisition of Pandion Therapeutics
Merck completed its acquisition of Pandion Therapeutics through a merger of a wholly owned Merck subsidiary with Pandion. Pandion became a wholly owned subsidiary of Merck, and its common stock was to be delisted from Nasdaq.
2021
Merck announces Caroline Litchfield as CFO
Merck announced Caroline Litchfield's appointment as executive vice president and chief financial officer, effective April 1, 2021.
2021
Cedar Clinical Research selected for Merck depression trial
Novamind announced that its subsidiary Cedar Clinical Research was selected as a key research site for Merck's clinical trial focused on treatment-resistant depression.
2021
M2GEN and Merck announce five-year oncology data agreement
M2GEN announced a new five-year agreement with Merck under which M2GEN will provide patient-consented, de-identified, linked clinical and genomic data to support Merck's oncology efforts.
2021
Dracen and Merck enter clinical trial and supply agreement for sirpiglenastat and KEYTRUDA
Dracen announced that it had entered into a clinical trial and supply agreement with Merck to evaluate sirpiglenastat in combination with KEYTRUDA in patients with solid tumors. The announced Phase 1b trial is expected to begin by the first quarter of 2022.
2021
Merck renames Performance Materials business to Electronics
Merck changed the name of its Performance Materials business to Electronics. The article says the new name is intended to clarify its business scope and focus its market positioning on the electronics industry.
2021
Merck and Guangzhou Pharmaceutical Group sign strategic cooperation memorandum
Merck and Guangzhou Pharmaceutical Group signed a strategic cooperation memorandum in Guangzhou to explore cooperation in business-model innovation, product research and development, and market expansion.
2021
Merck launches Milli-Q EQ 7000 in India
Merck launched its Milli-Q EQ 7000 Type 1 water purification system in India. The system was available for purchase and would replace the Milli-Q Reference and Reference A+ systems.
2021
Merck China Innovation Center and Huchuang United sign AI-assisted reproduction collaboration
Merck China Innovation Center and Huchuang United signed an innovation project agreement to collaborate on developing an AI-based system application for observing embryos in assisted reproduction.
2021
Merck announces CEO succession
Merck announced that CEO Kenneth Frazier would step down and be succeeded by the company's chief financial officer; Frazier would become executive chairman when the transition was expected at the end of June.
2021
Merck discontinues development of two COVID-19 vaccine candidates
Merck announced that it is discontinuing development of its COVID-19 vaccine candidates V590 and V591.
2021
Gardasil injury lawsuit filed against Merck
Robert F. Kennedy Jr. says he and Baum Hedlund filed a lawsuit against Merck alleging that its Gardasil HPV vaccine caused severe, life-changing injuries. The claims are allegations; the source reports no court determination.
2021
FDA approves Verquvo for adults with symptomatic chronic heart failure
The U.S. Food and Drug Administration approved Merck & Co.'s Verquvo to reduce cardiovascular death and heart failure hospitalization risk in specified adults with symptomatic chronic heart failure.
2021
MyID and Merck launch patient-support partnership
MyID announced that it had launched a partnership with Merck to provide the MyID mobile app and wristband to U.S. patients being treated with KEYTRUDA. Merck will procure the products directly from MyID and provide them to its KEYTRUDA patients through December 31, 2023.
2021
Janux and Merck enter a cancer research and development partnership
Merck entered an agreement with Janux Therapeutics to collaborate on two cancer targets selected by Merck. Merck will fund research and development of both programs, and Janux may receive royalties on resulting products.
2021
Merck announces acquisition of AmpTec
Merck announced its acquisition of Hamburg-based mRNA contract development and manufacturing organization AmpTec. The companies did not disclose the financial terms.
2021
Symvivo and Merck enter research collaboration
Symvivo Corporation entered into a research collaboration with Merck Sharp and Dohme Corp. concerning research to advance oral vaccine delivery. The agreement gives Merck an option to take an exclusive license to Symvivo’s bacTRL platform for advancing oral vaccine delivery.